November 22, 2016
A Delaware federal judge has ruled that drugmaker Actavis Elizabeth LLC infringed an Orexo AB patent with its planned generic version of opioid addiction treatment Zubsolv, a ruling Orexo said will keep Actavis from commercializing its product until 2019.